Addendum to: Genetics in Medicine 7:650–654 (2005); https://doi.org/10.1097/01.gim.0000186545.83160.1e, published online 01 November 2005
This document was retired by the ACMG Board of Directors as of 18 May 2020 with the following addendum:
Due to technological advances in the field of cytogenetics, and their resultant impact on the practice of clinical genetics since publication of this guideline, this document has been retired. Guidance from the ACMG regarding current application of cytogenetic technologies, including chromosome microarray (CMA) in the clinical genetic evaluation of individuals with developmental delay, intellectual disability, or autism spectrum disorders, is available.1,2
References
Manning M, Hudgins L, Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010;12:742–745.
Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15:399–407.
Author information
Authors and Affiliations
Consortia
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Correspondence: ACMG (documents@acmg.net)
Rights and permissions
About this article
Cite this article
Esplin, E.D., American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee. Addendum: American College of Medical Genetics guideline on the cytogenetic evaluation of the individual with developmental delay or mental retardation. Genet Med 22, 2128 (2020). https://doi.org/10.1038/s41436-020-0875-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41436-020-0875-5
